PROTEO INC
PROTEO INC (PTEO): 1 pipeline candidate · ~34 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
33.5 months
D/E -1.85 · 0% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for PROTEO INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$285K
Quarterly Burn
$29K
Runway
33.5 mo
Revenue
$481
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| elafin | Preclinical |
Frequently asked questions
How many drug candidates are in PROTEO INC's pipeline?
PROTEO INC (PTEO) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is PROTEO INC's lead drug candidate?
PROTEO INC's most advanced tracked candidate is elafin (Preclinical) for Pulmonary arterial hypertension.
What is PROTEO INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PROTEO INC has approximately 33.5 months of cash runway.
Who is the CEO of PROTEO INC?
Oliver Wiedow is the chief executive officer of PROTEO INC (PTEO).
Get the full picture on PROTEO INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.